Fig. 5: Analytical performance of CRISPR MN targeting different cfDNA in vitro.
a Schematic of CRISPR MN preparation. b Real-time CRISPR MN I response targeting variable concentrations of EBV cfDNA, in the presence of the simulated ISF solution. c Slope values of different target detection, data collected from the curve peak of the real-time curve calculated by simple differentiation, the slope of EBV cfDNA target compared with no target control (NTC) using two-way ANOVA: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, p value of 0.000092, 0.00038, 0.00027, 0.000096 for 30, 300, 3000, 30000 fM target DNA respectively, data presented as mean values ± SD, n = 3 independent experiments. d Standard calibration curve of the real-time I response from (b), data presented as mean values ± SD, n = 3 independent experiments. e Real-time CRISPR MN I response targeting variable concentrations of sepsis cfDNA, in the presence of the simulated ISF solution. f Real-time CRISPR MN I response targeting variable concentrations of kidney transplantation cfDNA, in the presence of the simulated ISF solution. g Signal response for sepsis cfDNA and kidney transplantation cfDNA in vitro including 3 × 10−12 M, 3 × 10−14 M, NTC, using two-way ANOVA: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, data presented as mean values ± SD, n = 3 independent experiments. h Dynamic change of sepsis cfDNA and kidney transplantation cfDNA recording by CRISPR MN platform, steps 1–3 referring to real-time monitoring of 3 × 10−14 M target cfDNA, 3 × 10−13 M target cfDNA, rinsed by TE buffer (37 °C, pH 8.0). i Anti-interference ability of the CRISPR MN for 3 × 10−12 M EBV cfDNA in the presence of various concentrations of fetal bovine serum. j The stable sensitivity of the CRISPR MN in vitro for 12 days, the CRISPR MN incubated in stimulated tissue and monitoring 3 × 10−14 M target cfDNA on a skin chip under reverse iontophoresis (10 V), data presented as mean values ± SD, n = 3 independent experiments.
